A phase II study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM with GM-CSF in patients with PSA progression after local therapy for prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2015
At a glance
- Drugs Rilimogene galvacirepvec (Primary) ; Rilimogene glafolivec (Primary) ; Sargramostim
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 29 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 03 Apr 2013 Planned end date changed from 1 Jul 2012 to 1 Jan 2023 as reported by ClinicalTrials.gov.